• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Diseases
leishmaniasis icon

Visceral leishmaniasis

Target product profile for visceral leishmaniasis

Home > Diseases
leishmaniasis icon

Visceral leishmaniasis

Target product profile for visceral leishmaniasis

  • Overview
  • Facts
  • Projects & achievements
  • Target product profiles

DNDi aims to develop a treatment for visceral leishmaniasis that is active against resistant strains and is suitable for all populations, including pregnant women and immune-compromised/-suppressed patients, with a maximum duration of ten days for once-daily oral treatment or three intramuscular injections.

Target product profile for primary visceral leishmaniasis

IdealAcceptable
Target population Patients with visceral leishmaniasis

Immunocompetent and immunosuppressed
Patients with visceral leishmaniasis

Immunocompetent
Target speciesAll species

Active against resistant strains
L. donovani

Active against resistant strains
Geographic distributionAll areasEither India or Africa
Efficacy >95% >90%
Safety/tolerabilityNo adverse events requiring monitoring1 monitoring visit at mid-/end-point
ContraindicationsNonePregnancy/lactation
Drug-drug interactionsNone – compatible for combination therapyNone for concomitant therapies for malaria, TB, and HIV
FormulationOral/ intramuscular Oral/ intramuscular
Treatment regimenOral: 1/day for 10 days
Intramuscular: 3 shots over 10 days
Bid for <10 days oral
>3 intramuscular injections over 10 days
Stability3 years in climatic zone IVStable under conditions that can be reasonably achieved in the target region (>2 years)
Cost<USD 10/course<USD 80/course

DNDi aims to develop an all-oral one-week combination treatment for visceral leishmaniasis that is active against resistant strains and suitable for all populations, including pregnant women and immunocompromised/-suppressed patients.

Target product profile for visceral leishmaniasis combination therapies

Ideal Acceptable
Target populationPatients with visceral leishmaniasis and PKDL

Immunocompetent and immunosuppressed
Patients with primary visceral leishmaniasis

Immunocompetent
Target speciesAll species

Active against resistant strains
L. donovani

Active against resistant strains
Geographic distributionAll areasEastern Africa
Efficacy≥95%≥90%
Safety/tolerabilityNo adverse events (AEs) requiring monitoring1 monitoring visit at mid-/end-point OR baseline assessment to exclude high-risk groups (dependent on the profile of the drug) and self-report if AEs
ContraindicationsNonePregnancy/lactation
Drug-drug interactionsNo interactions between the drugs to be combined for visceral leishmaniasis treatment, or with those used for other common co-morbidities (malaria, TB, HIV)No interactions between the drugs to be combined for visceral leishmaniasis treatment
FormulationOral/oralOral/ intramuscular injections
Intravenous injections could be acceptable
Treatment regimenSingle dose treatment or fixed-dose combination tablet/paediatric formulation up to 7 daysCurrently existing drugs: twice daily for ≤28 days oral; and intramuscular injections ≤14 days
Stability3 years in climatic zone IV2 years in climatic zone IV
CostTo be definedTo be defined

DNDi aims to develop an oral, maximum four-week daily treatment for PKDL in all patients and all regions, including pregnant women and immunocompromised patients (especially those co-infected with HIV).

Target product profile for post-kala-azar dermal leishmaniasis

IdealAcceptable
Target populationAll patients with PKDL

Pregnant women, but delay treatment after delivery

Immunocompromised patients (especially HIV co-infected patients)
All in South Asia persistent (>6 months) or grade 3 PKDL in Eastern Africa + grade 2 severe presentation

No studies done in pregnant women

Regimen adapted for immunocompromised patients (especially HIV co-infected patients)

Immunocompetent
Target speciesL. donovaniL. donovani
Geographic distributionAll areasAdapted by region (Asia or Africa)
Efficacy

Complete clinical cure:
– 100% disappearance of papules or nodules by 12 weeks
– 80% improvement in macular lesions with re-pigmentation
>90% efficacy

[Pharmacokinetics of new chemical entities: penetration in the skin should also favour development for PKDL]
>80% efficacy
Safety/tolerabilityNo adverse events (AEs) requiring monitoring

Well tolerated

All AEs ≤ grade 1
No major safety concerns
Acceptable for patient to come for one follow-up visit during treatment

Well tolerated in >90% of patients treated
Systemic AE > grade 2 in < 5%
No treatment-induced mortality
No irreversible AEs
ContraindicationsNoneAssessed by qualified person at primary health care/district hospital level, as per local context
FormulationOralOral or combination oral-parenteral
Treatment regimen≤4 weeks treatment once per day Twice daily for up to 6 weeks oral (regardless of PKDL presentation)
Up to 2 weeks if intramuscular injections
Up to 7 injections if intravenous injections
Stability≥3 years in climatic zone IV2 years in 4-8°C
Stable under storage at <30° C in case of self-administered
Cost<EUR 60 <EUR 100 for treatment (Ministry of Health)

Making medical history for neglected patients

We develop urgently needed treatments for neglected patients and ensure they’re affordable, available, and adapted to the communities who need them

Young boy sitting on a hospital bed being examined by a nurse

Chagas disease

Causes heart and vital organ damage, after people are bitten by blood-sucking bugs

We delivered the first-ever treatment for children; now we’re searching for new drug candidates and working to boost access to care

Patient medical examination

Cryptococcal meningitis

Without treatment, deadly for thousands of people with advanced HIV

We’re working to improve access to life-saving treatments and developing an easier-to-use formulation

Girl with skin lesions on her nose

Cutaneous leishmaniasis

Leaves disfiguring, life-long scars that lead to severe social stigma

We’re working to develop safer, shorter treatments for this disabling disease

Doctor with young patient in hospital setting

Dengue

Rapidly spreading climate-sensitive disease with no specific treatment

We’re building a global partnership with dengue-endemic countries to develop a first treatment

Father walking in rural village with a cane and holding his son's hand

Filaria: river blindness

Lead to unbearable itching, disfiguring skin lesions, and even blindness

We’re working to develop a safe, effective, and affordable drug for the prevention and treatment of this debilitating disease

Young man standing in the street

Hepatitis C

Millions are left without treatment even though effective drugs exist

We’ve delivered a treatment as simple, safe, and effective as the best drugs available today – at a fraction of the cost 

Woman standing in front of her door house in a rural village in Sudan

Mycetoma

Often ends in amputation​, after people get infected from stepping on a thorn

We conducted the world’s first trial for an alternative to current treatments, which are toxic and difficult to administer

Mother holding her baby in her arms smiling

Paediatric HIV

Without treatment, half of children die before their second birthday

We’ve developed a strawberry-flavoured treatment to meet the needs of children long neglected by the global HIV response

Healthcare workers in a hospital

Pandemic Preparedness

The COVID-19 pandemic intensified global health inequalities

We’re bringing together partners and accelerating research to prepare for future viral pandemics in low-resource settings

Doctor diagnosing a man in a village with his hands on the man's neck

Sleeping sickness

Transmitted by the bite of a tsetse fly and causes severe neurological disorders

We delivered a revolutionary new drug to replace toxic treatments, and have ongoing trials to eliminate this disease

Girl looking over a fence

Visceral leishmaniasis

Is one of the world’s biggest parasitic killers, spread by the bites of sandflies

We’re working to develop a new generation of treatments to replace drugs that are painful, ineffective, and cause side effects

Chagas disease

Cryptococcal meningitis

Cutaneous leishmaniasis

Dengue

Filaria: river blindness

Hepatitis C

Mycetoma

Paediatric HIV

Pandemic Preparedness

Sleeping sickness

Visceral leishmaniasis

VIEW ALL DISEASES

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License